Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741611 · ClinicalTrials.gov registry record · Phase 3
Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation
A Phase 3 study, sponsored by C. R. Bard.
- Terminated
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT00741611 is a Phase 3 study that was terminated before completion, run by C. R. Bard. The registered enrollment target is 44 participants.
The verdict
NCT00741611, a Phase 3 study, was terminated before completion, sponsored by C. R. Bard.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a randomized controlled study of the Bard High Density Mesh Ablation System for treatment of paroxysmal atrial fibrillation. This study will determine if the HD Mesh Ablation System is as safe as and more effective than anti-arrhythmic drugs.
Interventions
- DEVICE HD Mesh Ablation System
- DRUG Anti-arrhythmic drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741611
The ClinicalTrials.gov registry entry for NCT00741611 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HD Mesh Ablation System is the first listed.
NCT00741611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741611 about?
NCT00741611 is a clinical study titled "Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation". This is a randomized controlled study of the Bard High Density Mesh Ablation System for treatment of paroxysmal atrial fibrillation. This study will determine if the HD Mesh Ablation System is as safe as and more effective than anti-arrhythmic drugs.
What is the current status of trial NCT00741611?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2008-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00741611?
The interventions under investigation include: HD Mesh Ablation System (DEVICE), Anti-arrhythmic drugs (DRUG).
Who is sponsoring clinical trial NCT00741611?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.